Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides

Biomaterials

Volumn 34, Issue 16, 2013, Pages 4137-4149

  Gao, Wei ^a   Xiang, Bai ^a   Meng, Ting Ting ^a   Liu, Feng ^b   Qi, Xian Rong ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Cancer targeted therapy; Cell penetrating peptides; Docetaxel; Folate; Nanostructured lipid carrier (NLC); Tumor microenvironment sensitive polypeptides (TMSP)

Indexed keywords

CANCER-TARGETED THERAPY; CELL-PENETRATING PEPTIDE; DOCETAXEL; FOLATE; NANOSTRUCTURED LIPID CARRIER (NLC);

CELLS; CYTOLOGY; CYTOTOXICITY; DISEASES; DRUG DELIVERY; DRUG PRODUCTS; ENCAPSULATION; ENZYME ACTIVITY; ENZYME INHIBITION; MOLECULAR BIOLOGY; PEPTIDES; TOXICITY;

TUMORS;

DOCETAXEL; FOLATE RECEPTOR; FOLIC ACID; GELATINASE A; GELATINASE B; MACROGOL 2000; MALEIMIDE; NANOCARRIER; POLYPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; ENDOCYTOSIS; ENZYME RELEASE; HUMAN; HUMAN CELL; MOUSE; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUSTAINED DRUG RELEASE; TARGET CELL; TISSUE PRESSURE; TUMOR MICROENVIRONMENT; TUMOR MODEL;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; CELL-PENETRATING PEPTIDES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; FOLATE RECEPTORS, GPI-ANCHORED; FOLIC ACID; HUMANS; LIGANDS; MATRIX METALLOPROTEINASES; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NANOSTRUCTURES; NEOPLASMS; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SPHEROIDS, CELLULAR; TAXOIDS; TUMOR MICROENVIRONMENT;

MUS MUSCULUS;

EID: 84874952603     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.02.014     Document Type: Article

References (43)

1. Immordino M.L., Brusa P., Arpicco S., Stella B., Dosio F., Cattel L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J Control Release 2003, 91:417-429.
2. Lee E., Kim H., Lee I.H., Jon S. In vivo antitumor effects of chitosan-conjugated docetaxel after oral administration. J Control Release 2009, 140:79-85.
3. ® for tumor-targeted delivery of docetaxel. Biomaterials 2011, 32:7181-7190.
4. Lee S.W., Yun M.H., Jeong S.W., In C.H., Kim J.Y., Seo M.H., et al. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM™ using polymer-based delivery system. J Control Release 2011, 155:262-271.
5. Kumari A., Yadav S.K., Yadav S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2010, 75:1-18.
6. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011, 63:136-151.
7. Law B., Tung C.H. Proteolysis: a biological process adapted in drug delivery, therapy, and imaging. Bioconjug Chem 2009, 20:1683-1695.
8. Timar F., Botyanszki J., Suli-Vargha H., Babo I., Olah J., Pogany G., et al. The antiproliferative action of a melphalan hexapeptide with collagenase-cleavable site. Cancer Chemother Pharmacol 1998, 41:292-298.
9. Kline T., Torgov M.Y., Mendelsohn B.A., Cerveny C.G., Senter P.D. Novel antitumor prodrugs designed for activation by matrix metalloproteinases-2 and -9. Mol Pharm 2004, 1:9-22.
10. Denmeade S.R., Jakobsen C.M., Janssen S., Khan S.R., Garrett E.S., Lilja H., et al. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst 2003, 95:990-1000.
11. Kumar S.K., Williams S.A., Isaacs J.T., Denmeade S.R., Khan S.R. Modulating paclitaxel bioavailability for targeting prostate cancer. Bioorg Med Chem 2007, 15:4973-4984.
12. Devy L., de Groot F.M., Blacher S., Hajitou A., Beusker P.H., Scheeren H.W., et al. Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity. FASEB J 2004, 18:565-567.
13. Vartak D.G., Gemeinhart R.A. Matrix metalloproteases: underutilized targets for drug delivery. J Drug Target 2007, 15:1-20.
14. Shi N.Q., Gao W., Xiang B., Qi X.R. Enhancing cellular uptake of activable cell-penetrating peptide-doxorubicin conjugate by enzymatic cleavage. Int J Nanomedicine 2012, 7:1613-1621.
15. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002, 2:750-763.
16. Sabharanjak S., Mayor S. Folate receptor endocytosis and trafficking. Adv Drug Deliv Rev 2004, 56:1099-1109.
17. Leamon C.P., Reddy J.A. Folate-targeted chemotherapy. Adv Drug Deliv Rev 2004, 56:1127-1141.
18. Weitman S.D., Lark R.H., Coney L.R., Fort D.W., Frasca V., Zurawski V.R., et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1992, 52:3396-3401.
19. Jreyssaty C., Shi Q., Wang H., Qiu X., Winnik F.M., Zhang X., et al. Efficient nonviral gene therapy using folate-targeted chitosan-DNA nanoparticles in vitro. ISRN Pharm 2012, 2012:369270.
20. Ross J.F., Chaudhuri P.K., Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994, 73:2432-2443.
21. Lu Y., Low P.S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev 2002, 54:675-693.
22. Wender P.A., Mitchell D.J., Pattabiraman K., Pelkey E.T., Steinman L., Rothbard J.B. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci U S A 2000, 97:13003-13008.
23. Kibria G., Hatakeyama H., Harashima H. A new peptide motif present in the protective antigen of anthrax toxin exerts its efficiency on the cellular uptake of liposomes and applications for a dual-ligand system. Int J Pharm 2011, 412:106-114.
24. Gabizon A., Horowitz A.T., Goren D., Tzemach D., Mandelbaum-Shavit F., Qazen M.M., et al. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjug Chem 1999, 10:289-298.
25. Chau Y., Tan F.E., Langer R. Synthesis and characterization of dextran-peptide-methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase II and matrix metalloproteinase IX. Bioconjug Chem 2004, 15:931-941.
26. Zhang P., Ling G., Pan X., Sun J., Zhang T., Pu X., et al. Novel nanostructured lipid-dextran sulfate hybrid carriers overcome tumor multidrug resistance of mitoxantrone hydrochloride. Nanomedicine 2012, 8:185-193.
27. Giambernardi T.A., Grant G.M., Taylor G.P., Hay R.J., Maher V.M., McCormick J.J., et al. Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol 1998, 16:483-496.
28. Chau Y., Padera R.F., Dang N.M., Langer R. Antitumor efficacy of a novel polymer-peptide-drug conjugate in human tumor xenograft models. Int J Cancer 2006, 118:1519-1526.
29. Saul J.M., Annapragada A.V., Bellamkonda R.V. A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J Control Release 2006, 114:277-287.
30. Kim S.H., Kim J.K., Lim S.J., Park J.S., Lee M.K., Kim C.K. Folate-tethered emulsion for the target delivery of retinoids to cancer cells. Eur J Pharm Biopharm 2008, 68:618-625.
31. Canal F., Vicent M.J., Pasut G., Schiavon O. Relevance of folic acid/polymer ratio in targeted PEG-epirubicin conjugates. J Control Release 2010, 146:388-399.
32. Watanabe K., Kaneko M., Maitani Y. Functional coating of liposomes using a folate- polymer conjugate to target folate receptors. Int J Nanomedicine 2012, 7:3679-3688.
33. Bawadi H.A., Antunes T.M., Shih F., Losso J.N. In vitro inhibition of the activation of pro-matrix metalloproteinase 1 (Pro-MMP-1) and pro-matrix metalloproteinase 9 (Pro-MMP-9) by rice and soybean Bowman-Birk inhibitors. J Agric Food Chem 2004, 52:4730-4736.
34. Aguilera T.A., Olson E.S., Timmers M.M., Jiang T., Tsien R.Y. Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integr Biol (Camb) 2009, 1:371-381.
35. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
36. Haycock J.W. 3D cell culture: a review of current approaches and techniques. Methods Mol Biol 2011, 695:1-15.
37. Friedrich J., Ebner R., Kunz-Schughart L.A. Experimental anti-tumor therapy in 3-D: spheroids - old hat or new challenge?. Int J Radiat Biol 2007, 83:849-871.
38. Kunz-Schughart L.A., Freyer J.P., Hofstaedter F., Ebner R. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J Biomol Screen 2004, 9:273-285.
39. Del Duca D., Werbowetski T., Del Maestro R.F. Spheroid preparation from hanging drops: characterization of a model of brain tumor invasion. J Neurooncol 2004, 67:295-303.
40. Roy R., Yang J., Moses M.A. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009, 27:5287-5297.
41. Pearce T.R., Shroff K., Kokkoli E. Peptide targeted lipid nanoparticles for anticancer drug delivery. Adv Mater 2012, 24:3803-3822. 710.
42. Minchinton A.I., Tannock I.F. Drug penetration in solid tumours. Nat Rev Cancer 2006, 6:583-592.
43. Tong S.W., Xiang B., Dong D.W., Qi X.R. Enhanced antitumor efficacy and decreased toxicity by self-associated docetaxel in phospholipid-based micelles. Int J Pharm 2012, 434:413-419.